Tucidinostat clinical trials
Tucidinostat is named as an intervention in 6 current clinical trials in our China and Taiwan registers. 5 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Ou Bai, MD/PHD (2). The most-studied condition is Diffuse Large B-Cell Lymphoma (DLBCL).
How Tucidinostat works
All drug targets →- Inhibits HDAC1 Primary targetTarget: HDAC1 histone deacetylase 1Guide to Pharmacology only
- Acute myeloid leukemiaPhase 3
- Breast cancerPhase 3
- Colorectal cancerPhase 3
- Diffuse large B-cell lymphomaPhase 3
- Mature T-cell and NK-cell non-Hodgkin lymphomaPhase 3
- MelanomaPhase 3
- Peripheral T-cell lymphoma, not otherwise specifiedPhase 3
- HIV infectious diseasePhase 2/3
- T-lymphoblastic lymphomaPhase 2/3
- Acute lymphoblastic leukemiaPhase 2/3
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL3621988, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 8305, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Tucidinostat
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Reference identifiers for Tucidinostat
- ChEMBL
- CHEMBL3621988
- DrugBank
- DB06334
- PubChem CID
- 12136798
- CAS number
- 1616493-44-7
- FDA UNII
- 87CIC980Y0
- Wikidata
- Q19903814
- Wikipedia
- Tucidinostat
Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.
Trials by status
Trials by phase
Clinical trials of Tucidinostat
6 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Tucidinostat
5 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Ou Bai, MD/PHD | 2 |
| Chipscreen Biosciences, Ltd | 2 |
| Zhongshan Hospital (Xiamen), Fudan University | 1 |
| Great Novel Therapeutics Biotech & Medicals Corporation | 1 |
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 5 | 4 |
| Clinical trials in Taiwan | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Tucidinostat trials
How many clinical trials are testing Tucidinostat?
6 current trials in our China and Taiwan registers name Tucidinostat as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are Tucidinostat trials recruiting patients?
Yes. 5 of the 6 trials are recruiting: 4 with sites in China and 1 with sites in Taiwan. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Tucidinostat clinical trials?
Ou Bai, MD/PHD (2), Chipscreen Biosciences, Ltd (2), Zhongshan Hospital (Xiamen), Fudan University (1) and Great Novel Therapeutics Biotech & Medicals Corporation (1). The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Tucidinostat works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Tucidinostat works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Tucidinostat (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.